Anaïs Andrillon

Mogamulizumab induces long‐term immune restoration and reshapes tumour heterogeneity in Sézary syndrome *

L. Biard, A. Toubert, M. Bagot, 2022, The British journal of dermatology.

Surv‐CRM‐12: A Bayesian phase I/II survival CRM for right‐censored toxicity endpoints with competing disease progression

Shing M. Lee, S. Chevret, L. Biard, 2022, Statistics in medicine.

Anti-TNF-α versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network.

L. Biard, D. Sène, P. Cacoub, 2021, Ophthalmology.

Performance of propensity score matching to estimate causal effects in small samples

S. Chevret, R. Pirracchio, A. Andrillon, 2020, Statistical methods in medical research.

Dose-finding design and benchmark for a right censored endpoint

Shing M. Lee, S. Chevret, L. Biard, 2020, Journal of biopharmaceutical statistics.

Dose optimization for cancer treatments with considerations for late-onset toxicities

Anaïs Andrillon, Rebecca B. Silva, Lucie Biard, 2024, Clinical trials.